Trial reportGut2006
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.
Trial report in Gut, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 86 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Who cites it
86 citing papers in PubMed, 9 syntheses or guidelines pooled it, 256 citations in OpenAlex.
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Gut Microbiota Profiles and Microbial-Based Therapies in Post-operative Crohn's Disease: A Systematic Review.Frontiers in medicine · 2020Pooled it
- Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.The Cochrane database of systematic reviews · 2019Pooled it
- The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials.BioMed research international · 2015Pooled it
- Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review.BMJ open · 2014Pooled it
- Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis.World journal of gastroenterology · 2014Pooled it
- Pooled it
- Meta-analysis of probiotics for the treatment of irritable bowel syndrome.World journal of gastroenterology · 2008Pooled it
- On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials.Digestive diseases and sciences · 2008Pooled it
- Machine learning-based assessment of the healthy human gut mycobiota landscape using ITS1 DNA metabarcoding data.BioData mining · 2026Article
- Primary Prevention of Pouchitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- The Role of Intestinal Fungi in the Pathogenesis and Treatment of Ulcerative Colitis.Microorganisms · 2025Review
- Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Review
- Navigating Chronic Pouchitis: Pathogenesis, Diagnosis, and Management.Gastroenterology & hepatology · 2025Article
- Gut microbiota - bidirectional modulator: role in inflammatory bowel disease and colorectal cancer.Frontiers in immunology · 2025Review
- Aging and Intestinal Fibrosis: Mechanisms, Implications, and Therapeutic Strategies.Clinical interventions in aging · 2025Review
- Altered Bile Acid and Pouch Microbiota Composition in Patients With Chronic Pouchitis.Inflammatory bowel diseases · 2024Article
- Pouchitis: pathophysiology and management.Nature reviews. Gastroenterology & hepatology · 2024Review
- Global hotspots and trends in gut mycological research: a visual analytics and bibliometric approach.Frontiers in immunology · 2024Article
- Effects of Probiotics in Adults with Gastroenteritis: A Systematic Review and Meta-Analysis of Clinical Trials.Diseases (Basel, Switzerland) · 2023Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe intestinal microbiota plays a critical role in the pathophysiology of pouchitis, a major complication after ileal pouch anal anastomosis in patients with ulcerative colitis. Recently, controlled trials have demonstrated that probiotics are effective in maintenance of remission in pouchitis patients. However, the mechanism by which therapy with probiotics works remains elusive. This study explores the role of the bacterial and fungal flora in a controlled trial for maintenance of remission in pouchitis patients with the probiotic VSL#3 compound.
methodsThe mucosa associated pouch microbiota was investigated before and after therapy with VSL#3 by analysis of endoscopic biopsies using ribosomal DNA/RNA based community fingerprint analysis, clone libraries, real time polymerase chain reaction (PCR), and fluorescence in situ hybridisation. Patients were recruited from a placebo controlled remission maintenance trial with VSL#3.
resultsPatients who developed pouchitis while treated with placebo had low bacterial and high fungal diversity. Bacterial diversity was increased and fungal diversity was reduced in patients in remission maintained with VSL#3 (p = 0.001). Real time PCR experiments demonstrated that VSL#3 increased the total number of bacterial cells (p = 0.002) and modified the spectrum of bacteria towards anaerobic species. Taxa specific clone libraries for Lactobacilli and Bifidobacteria showed that the richness and spectrum of these bacteria were altered under probiotic therapy.
conclusionsProbiotic therapy with VSL#3 increases the total number of intestinal bacterial cells as well as the richness and diversity of the bacterial microbiota, especially the anaerobic flora. The diversity of the fungal flora is repressed. Restoration of the integrity of a "protective" intestinal mucosa related microbiota could therefore be a potential mechanism of probiotic bacteria in inflammatory barrier diseases of the lower gastrointestinal tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.